Yuxiang Ma
North China Electric Power University(CN)Harbin Medical University(CN)Sun Yat-sen University(CN)Chinese Center For Disease Control and Prevention(CN)Dalian University of Technology(CN)Chinese PLA General Hospital(CN)Henan University of Technology(CN)Key Laboratory of Guangdong Province(CN)First Affiliated Hospital of Guangzhou Medical University(CN)Third Affiliated Hospital of Harbin Medical University(CN)Nanjing Drum Tower Hospital(CN)Guangzhou Institute of Dermatology(CN)Guangdong Institute of Intelligent Manufacturing(CN)Center for Special Minimally Invasive and Robotic Surgery(US)Sun Yat-sen University Cancer Center(CN)Guangdong Provincial People's Hospital(CN)State Key Laboratory of Oncology in South ChinaGuangzhou Medical University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials(2018)500 cited
- → EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy(2014)382 cited
- → Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer(2019)235 cited
- → Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer(2016)200 cited
- → Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition(2019)175 cited
- → Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer(2015)